ArticleCureus2025
Comparing Adductor Canal Blocks With Bupivacaine and Magnesium to Bupivacaine and Buprenorphine After Same-Day Discharge Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives Same-day discharge (SDD) total knee arthroplasty (TKA) can provide significant cost savings when compared to inpatient TKA. Advances in surgical techniques, early mobilization, and perioperative pain control have been the primary facilitators of this move toward SDD. Using adjuvant medications, such as magnesium and buprenorphine, along with local anesthetics in regional anesthetic techniques has been shown to be effective in prolonging analgesic effects. The objective of this study was to compare the effects of using magnesium and bupivacaine to buprenorphine and bupivacaine in adductor canal blocks (ACB) on postoperative pain, opioid consumption, nausea, and overall satisfaction. Methods A total of 105 adults undergoing elective unilateral SDD TKA were included. An a priori power analysis was conducted using G*Power 3.1.6 (Heinrich Heine University Düsseldorf, Düsseldorf, Germany) to calculate sample size. Patients were randomly assigned to receive ACB with magnesium and bupivacaine (n = 62) or buprenorphine and bupivacaine (n = 43). Primary outcomes were opioid consumption and pain scores for the first 48 hours after surgery. Secondary outcomes included the incidence of nausea in the first 48 hours after surgery and overall satisfaction with the surgical experience measured using a Likert scale from 0 to 10. Results There was no significant difference in pain scores in the magnesium group compared to the buprenorphine group over the first 24 hours (4.1 ± 1.8 vs. 3.7 ± 1.9, P = 0.375) and the second 24 hours (4.4 ± 2.2 vs. 4.2 ± 1.9, P = 0.637) after surgery. The difference in opioid consumption was also nonsignificant when comparing the magnesium group to the buprenorphine group over the first 24 hours (61.4 ± 50.6 vs. 47.4 ± 39.2, P = 0.108), the second 24 hours (33.0 ± 40.1 vs. 21.7 ± 20.8, P = 0.590), and the first 48 hours (28.0 ± 19.9 vs. 25.7 ± 21.2, P = 0.148) total after surgery. Secondary outcomes showed no difference in the incidence of nausea over the first 48 hours and overall satisfaction. Conclusion Magnesium and buprenorphine are comparable as adjuvants in their effects on postoperative pain and opioid consumption at 24 and 48 hours after SDD TKA, with similar incidences of nausea and vomiting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.